NEW YORK, August 7, 2017 /PRNewswire/ --
If you want a Stock Review on SRPT, TRVN, TSRO, or VRTX then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has issued research reports on Sarepta Therapeutics Inc. (NASDAQ: SRPT), Trevena Inc. (NASDAQ: TRVN), Tesaro Inc. (NASDAQ: TSRO), and
Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.'s stock rose 1.69%, finishing last Friday's trading session at $38.52. A total volume of 1.50 million shares was traded. The Company's shares have gained 13.09% in the last month, 17.98% over the previous three months, and 40.43% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.78% and 14.33%, respectively. Additionally, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have a Relative Strength Index (RSI) of 54.83.
On July 20th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $60 a share to $64 a share.
On July 27th, 2017, Sarepta Therapeutics announced the publication of data validating Genethon's micro-dystrophin gene therapy approach in an animal model for Duchenne muscular dystrophy (DMD). The results were featured in the July 25th, 2017 online issue of Nature Communications. The Company announced in June 2017 that it entered into exclusive gene therapy research collaboration with Genethon to jointly develop treatments for DMD. See our free and comprehensive research report on SRPT at:
Shares in King of Prussia, Pennsylvania headquartered Trevena Inc. ended at $2.43, jumping 4.74% from the last trading session. The stock recorded a trading volume of 426,384 shares. The Company's shares have advanced 5.65% in the past month. The stock is trading 4.90% below its 50-day moving average. Moreover, shares of Trevena, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 43.73.
On August 03rd, 2017, Trevena announced financial results for the quarter ended June 30th, 2017. Net loss for Q2 2017 was $20.4 million; research and development expenses were $15.5 million; and general and administrative expenses were $4.4 million. Cash, cash equivalents, and marketable securities were $84.2 million as of June 30th, 2017. TRVN free research report is just a click away at:
On Friday, shares in Waltham, Massachusetts headquartered Tesaro Inc. recorded a trading volume of 711,508 shares. The stock climbed 3.24%, closing the day at $128.59. The Company's shares are trading 6.80% below their 50-day moving average. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 47.58.
On July 07th, 2017, research firm Gabelli & Co initiated a 'Buy' rating on the Company's stock, with a target price of $175 per share.
On July 25th, 2017, Tesaro announced that the Company will release its Q2 2017 financial results on August 08th, 2017, after the close of the US financial markets. The senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on that same day to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI/Y® and ZEJULATM launches. Sign up for your complimentary report on TSRO at:
At the close of trading on Friday, shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. recorded a trading volume of 806,212 shares. The stock finished the session 0.33% higher at $154.54. The Company's shares have surged 20.30% in the past month, 34.57% in the previous three months, and 109.77% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 14.59% and 50.18%, respectively. Furthermore, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 60.25.
On July 19th, 2017, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On July 26th, 2017, Vertex Pharma reported consolidated financial results for the second quarter ended June 30th, 2017. Total CF net product revenues were $514.0 million for the quarter, net product revenues from ORKAMBI were $324.4 million, and net product revenues from KALYDECO were $189.6 million. As of June 30th, 2017, the Company had $1.67 billion in cash, cash equivalents and marketable securities. Register for free on DailyStockTracker.com and download the latest research report on VRTX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...View All